AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesicmedication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabis blends in Japan, along with a related compound AB-PINACA, which had not previously been reported.
Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. AB-FUBINACA is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
Unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and toxicity in general. Therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.
- [+]3Subjective effects
- [+]4Toxicity and harm potential
- 5Legal issues
- 6See also
- 7External links
Although this substance has not been formally studied, from analysis of the structure, it is presumed that AB-FUBINACA has a similar binding profile to that of other cannabinoids and matches many of the in vivo properties of Δ9-THC. As with the compounds within cannabis, AB-FUBINACA exhibits its range of effects via full agonism of both the CB1 and CB2cannabinoid receptors, with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.
Subjective effects of AB-FUBINACA
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWikicontributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.
Mass Overdoses in New Haven, Connecticut 2018
On August 15th, 2018, 70 people within the city of New Haven, Connecticut started overdosing near Yale University campus. By the end of the week, the total number of overdosed had risen to over 100 people needing transport to local emergency rooms. Three men were arrested, charged as drug dealers selling synthetic cannabis, which was laced with the drug AB-FUBINACA. Police originally said the drugs were laced with fentanyl.
New Haven Police arrested John Parker, 53, on charges of possession with intent to sell after finding 32 bags of “K2”, or “spice,” in his house. He was also charged in connection with a February police operation. NHPD said Felix Melendez, 37, was also arrested charged with possession of a controlled substance. Melendez was on probation for a prior conviction of selling K2 at the park. Almost all of the overdoses occurred on the New Haven Green, a large downtown park that is heavily traveled and very popular with the homeless population. The 3rd Suspect that was arrested by Federal Authorities has not been named.
There have been no deaths associated with the overdoses. However, several victims are in critical or life-threatening condition.